2D vs 3D gamma analysis: Establishment of comparable  clinical action limits by Pulliam, Kiley B et al.
International Journal of Cancer Therapy and Oncology 
www.ijcto.org 
Copyright © Pulliam et al.                                                                                     ISSN 2330-4049 
2D vs 3D gamma analysis: Establishment of comparable   
clinical action limits   
Kiley B Pulliam1, Jessie Y Huang1, Ryan Bosca1, David Followill2, Stephen F Kry2 
 
1The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA. 
2Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 
 
Received March 19, 2014; Published Online April 08, 2014 
[Presented at the Young Investigator’s Symposium at the 2014 Annual Meeting of  
Southwest Chapter of American Association of Physicists in Medicine (AAPM) in San Antonio, Texas, USA] 
Conference Proceeding 
Abstract 
Purpose: As clinics begin to use 3D metrics for intensi-
ty-modulated radiation therapy (IMRT) quality assurance; 
these metrics will often produce results different from those 
produced by their 2D counterparts. 3D and 2D gamma anal-
yses would be expected to produce different values, because 
of the different search space available. We compared the 
results of 2D and 3D gamma analysis (where both datasets 
were generated the same way) for clinical treatment plans. 
  
Methods: 50 IMRT plans were selected from our database and 
recalculated using Monte Carlo. Treatment planning sys-
tem-calculated (“evaluated”) and Monte Carlo-recalculated 
(“reference”) dose distributions were compared using 2D and 
3D gamma analysis. This analysis was performed using a 
variety of dose-difference (5%, 3%, 2%, and 1%) and dis-
tance-to-agreement (5, 3, 2, and 1 mm) acceptance criteria, 
low-dose thresholds (5%, 10%, and 15% of the prescription 
dose), and data grid sizes (1.0, 1.5, and 3.0 mm). Each com-
parison was evaluated to determine the average 2D and 3D 
gamma and percentage of pixels passing gamma.  
 
Results: Average gamma and percentage of passing pixels for 
each acceptance criterion demonstrated better agreement for 
3D than for 2D analysis for every plan comparison. Average 
difference in the percentage of passing pixels between the 2D 
and 3D analyses with no low-dose threshold ranged from 
0.9% to 2.1%. Similarly, using a low-dose threshold resulted 
in a differences ranging from 0.8% to 1.5%. No appreciable 
differences in gamma with changes in the data density (con-
stant difference: 0.8% for 2D vs. 3D) were observed. 
 
Conclusion: We found that 3D gamma analysis resulted in up 
to 2.9% more pixels passing than 2D analysis.  Factors such 
as inherent dosimeter differences may be an important addi-
tional consideration to the extra dimension of available data 
that was evaluated in this study. 
------------------------------------------------------------------- 
 
FIG. 1: (a) 2D and (b) 3D gamma maps of the same transverse slice of 
the gamma comparison in a homogenous QA phantom showing 
gamma failure (i.e.  >1) in the 2D map (average  = 1.04) but passing 
in the 3D map (average  = 0.52) for the 3%/3-mm acceptance crite-
ria with a 15% low-dose threshold. 
 
Key Results: 
2D vs. 3D gamma for different QA evaluation criteria:  
The average gamma value and percentage of pixels 
passing gamma for the comparisons of 2D and 3D 
gamma with a variety of dose-difference and DTA cri-
teria for the 50 QA plans and 50 corresponding patient 
plans are shown in Table 1. Overall, for each ac-
ceptance criterion, the 3D gamma was lower than the 
2D gamma (i.e., better agreement), on average for both 
the QA and patient plans. The differences between the 
average 2D and 3D gamma and percentage of pixels 
were statistically significant (P < 0.001) for both QA 
and patient plans. 
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TABLE 1: Average 2D vs. 3D gammas and percentages of pixels passing gamma values for the (a) 50 QA and (b) 50 patient plans at the 5%/5-mm, 
3%/3-mm, 2%/2-mm, and 1%/1-mm acceptance criteria with no low-dose threshold and a 1-mm data grid.  
Acceptance 
criteria Average 2D gamma  Average 3D gamma 
Average 2D percentage of 
pixels passing gamma 
Average 3D percentage of 
pixels passing gamma 
5%/5 mm 0.22  0.20  98.3  98.7  
3%/3 mm 0.37  0.33  96.6  97.4  
2%/2 mm 0.56  0.51  93.2  94.9  





criteria Average 2D gamma  Average 3D gamma 
Average 2D percentage of 
pixels passing gamma 
Average 3D percentage of 
pixels passing gamma 
5%/5 mm 0.25  0.22  98.0  98.9  
3%/3 mm 0.44  0.37  94.2  96.4  
2%/2 mm 0.71  0.59  88.8  91.7  
1%/1 mm 1.85  1.58  74.9  77.0  
(b) 
Application to IMRT QA: In general, there are many differences between planar and volumetric analysis for IMRT QA. Indi-
vidual planes in 2D analysis may miss problems that would be identified with 3D analysis, but could also highlight local regions 
where problems exist. Figure 1 shows a clinical plan in which the same single transverse slice failed 2D gamma QA ( = 1.04) 
but easily passed 3D gamma QA ( = 0.52). This sort of case likely represents a scenario where a plan “failed” based on 2D analy-
sis that should have, in reality, passed, as indicated in the 3D analysis.   
 
 
 
 
 
 
